The study further characterizes an insulin antagonist in diabetic acidosis serum, showing it is an alpha-globulin protein that inhibits insulin without competing for binding sites.
Answers are grounded in this paper and cite their sources.
Further characterizes serum insulin antagonist; leaves open its role in human diabetic acidosis pending clinical studies.
We have previously described an insulin antag- onist in the sera of patients in diabetic acidosis (1, 2). The protein nature of this material was suggested by its lability at 1000 C. and its electrophoretic migration with the a-globulins. The an- tagonist was not a lipoprotein and did not exhibit any insulinase activity. Its inhibitory effect was still demonstrable whether it was added to the hemidiaphragm preparation before or after ex- posure to insulin. Experiments using insulin-I'81 indicated that the antagonist did not compete with insulin for binding sites on diaphragm (2).
No takes yet. Share an insight, caveat, or question.
Field et al. (1957) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: